News and Announcements
Novogen CEO interviewed on CommSec
- Published July 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
CommSec released an interview today as part of its Executive Series, featuring Executive Director and CEO, Dr James Garner.
KEY TAKEAWAYS:
- Tom Piotrowski talks with Dr Garner about Novogen’s business model and the way it is being used to bring to market the best of available cancer treatments.
- Providing an overview of Novogen’s pipeline.
Dr Garner talked about the next steps for the Company’s lead candidate GDC-0084, a drug to treat Glioblastoma Multiforme. GDC-0084 was licenced from Genentech, and showed great promise in a Phase I clinical trial. A Phase II clinical trial is expected will start later this year.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
